News
Public · Published
Heidelberg Pharma to Present New Clinical Data on its ATAC Candidates at the ASH Annual Meeting 2026
Heidelberg Pharma said it will present new data from its Phase I/IIa study of lead candidate HDP-101 in an oral session at the ASH Annual Meeting, and data on HDP-102 in a poster session. The meeting is scheduled for 12–15 December 2026 in New Orleans.
Published:
Updated:
What happened
Heidelberg Pharma said it will present new data from its Phase I/IIa study of lead candidate HDP-101 in an oral session at the ASH Annual Meeting, and data on HDP-102 in a poster session. The meeting is scheduled for 12–15 December 2026 in New Orleans.
Confirmed
Global impact / market context
The presentations will provide clinical information on two drug candidates, including preliminary antitumor activity and selection of a recommended Phase 2 dose for HDP-101. If the data support continued development, they could influence research priorities and future spending, but the announcement gives no results or funding plans.
Analyst inference
Heidelberg Pharma describes itself as a clinical-stage company, meaning its candidates are still being tested in people rather than sold as established medicines. The announcement concerns scheduled research presentations, not a reported treatment approval, commercial launch, or confirmed change to the company’s finances.
Confirmed
What to watch
- At the December meeting, watch for the actual HDP-101 results, especially the preliminary antitumor activity and the recommended Phase 2 dose described in the presentation title. Analyst inference
- Watch for the HDP-102 poster data and any details about the candidate’s study; the announcement confirms a poster presentation but does not describe its results. Confirmed
- Further development decisions could require additional clinical testing and spending; watch for company updates on study plans, timing, and funding, none of which are specified here. Analyst inference